Larazotide acetate: complete guide

Larazotide acetate is an eight-amino-acid tight junction regulator. Its phase 3 celiac trial stopped in 2022, and it is not FDA-approved for any use.

Complete guide6 min read

Key takeaway

Larazotide has 8 amino acids (GGVLVQPG) and a molecular weight of 725.8 g/mol as the free peptide. In a phase 2 trial of 342 adults with celiac disease, only one of three larazotide arms beat placebo on symptoms. The phase 3 trial enrolled 307 people before it was terminated.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“Larazotide acetate is not approved by the FDA for any use.” (this article)
ClassGut & digestion
Body systemsGut
Studies cited4 in this article · 4 across 1 article on Larazotide acetate
Related productsResearch peptide catalog

Larazotide acetate is an eight-amino-acid peptide designed to regulate tight junctions, the seals between cells that line the gut. It reached a phase 3 trial in celiac disease, which its sponsor stopped in 2022. Academic teams have since tested it in children with MIS-C and in long COVID. Sources were checked on November 17, 2026.

Quick answer: Larazotide acetate is an investigational peptide, not an approved drug. 9 Meters Biopharma stopped its phase 3 celiac disease trial in June 2022 and ended celiac development that August. A small trial in children with MIS-C reported no larazotide-related adverse events. A long COVID trial was completed in 2026 without posted results.

Vitrapep does not sell larazotide acetate; this page is a reference summary of published research and regulatory information.

What is larazotide acetate?

Larazotide is a linear peptide of eight amino acids: Gly-Gly-Val-Leu-Val-Gln-Pro-Gly, or GGVLVQPG. PubChem lists the free peptide as C32H55N9O10 with a molecular weight of 725.8 g/mol (PubChem CID 9810532). The acetate salt used in trials is C34H59N9O12 at 785.9 g/mol (PubChem CID 44146842).

It counts as a peptide because it is a short chain of amino acids joined by peptide bonds. Our peptide primer explains the basics. PubChem lists the code names AT-1001 and AT1001. On ClinicalTrials.gov, the code AT1001 also appears for migalastat, an unrelated Fabry disease drug. Searches by code alone can mix the two.

Table 1

Larazotide acetate: key facts

Fact Detail
Structure type Linear peptide of 8 amino acids (GGVLVQPG), as the acetate salt
Class Tight junction regulator (investigational)
Molecular formula C32H55N9O10 (larazotide); C34H59N9O12 (larazotide acetate)
Molecular weight 725.8 g/mol (larazotide); 785.9 g/mol (larazotide acetate)
Development stage Phase 3 in celiac disease terminated in 2022; academic phase 2 in long COVID completed in 2026
Sponsor or developer 9 Meters Biopharma (celiac trials); Massachusetts General Hospital (MIS-C and long COVID trials)

How does larazotide acetate work?

Tight junctions are protein seals that control what passes between neighboring cells. Larazotide is described as a tight junction regulator (Gopalakrishnan et al., 2012). In Caco-2 and IEC6 intestinal cell lines, it blocked the rearrangement of the junction protein ZO-1 and of actin. That rearrangement was triggered by gliadin fragments, from gluten, and by AT-1002, a peptide from a Vibrio cholerae toxin.

In the same cell work, larazotide reduced the leakiness caused by AT-1002 and by inflammatory cytokines. It also cut the passage of a gliadin fragment across cell layers. In gliadin-sensitized HLA-DQ8 transgenic mice, it reduced gliadin-induced macrophage build-up in the gut and helped preserve normal junction structure. These are cell and animal data.

What is larazotide acetate being studied for?

Larazotide acetate is not approved by the FDA for any use. ClinicalTrials.gov lists phase 1 and 2 celiac disease trials from 2005 to 2013, now under 9 Meters Biopharma. Key later records include:

  • celiac disease with persistent symptoms, phase 2, 342 adults, completed 2013 (NCT01396213);
  • celiac disease symptom relief, phase 3, 307 enrolled, terminated by the sponsor in 2022 (NCT03569007);
  • COVID-19-related MIS-C in children, phase 2, 12 enrolled, terminated after MIS-C cases declined (NCT05022303); and
  • long COVID in children and adults, phase 2a, 107 enrolled, completed June 2026, no results posted (NCT05747534).

Massachusetts General Hospital sponsors the MIS-C and long COVID trials. We found no company currently developing larazotide in a registered trial.

What did the key trials show?

Persistent celiac symptoms, phase 2. This randomized, double-blind, placebo-controlled trial enrolled 342 adults who had followed a gluten-free diet for at least 12 months. The primary endpoint was the average on-treatment celiac gastrointestinal symptom score. Only one of three larazotide arms met it (ANCOVA P = .022) (Leffler et al., 2015). That arm also showed a 26% drop in symptomatic days in exploratory analyses (P = .017). The other two arms did not differ from placebo. The authors called the results mixed.

Gluten challenge, phase 2. This exploratory trial randomized 184 people with celiac disease to larazotide or placebo during a daily gluten challenge. The primary endpoint, the lactulose-to-mannitol ratio of gut permeability, did not differ from placebo (Kelly et al., 2013). One larazotide arm limited gluten-induced symptoms (P = 0.002).

CedLara, phase 3. On June 21, 2022, 9 Meters reported a pre-specified interim analysis covering about half of the planned 525 patients. It said the extra patients needed to show a significant result made the trial “too large to support trial continuation” (9 Meters, 2022a). On August 15, 2022, it said it was “discontinuing further development of larazotide in celiac disease” (9 Meters, 2022b).

MIS-C, phase 2a. This randomized, double-blind, placebo-controlled trial enrolled 12 children hospitalized with post-COVID multisystem inflammatory syndrome. Treated children had faster resolution of gut symptoms, faster clearance of viral spike antigen and a quicker return to activities (Yonker et al., 2025). The authors said larazotide “may improve resolution of symptoms,” a preliminary finding given the size. All four studies were in humans.

What side effects have studies reported?

The published abstracts report safety in general terms:

  • 342-adult celiac trial: “Safety was comparable with placebo” (Leffler et al., 2015);
  • gluten challenge trial: “Adverse event rates were similar between larazotide acetate and placebo groups” (Kelly et al., 2013); and
  • MIS-C trial: “No larazotide-related adverse events were reported” (Yonker et al., 2025).

None of the larazotide records on ClinicalTrials.gov has posted results, so event-by-event rates are not available there. We found no published phase 3 safety data.

What is larazotide acetate’s regulatory status, and how is it used in research?

Larazotide acetate is an investigational compound in the United States. A search of fda.gov returned no FDA approval, designation, warning letter or import alert naming it. Its former commercial sponsor ended celiac development in 2022, and the remaining registered work is academic.

In laboratories, larazotide is a tool for studying tight junctions and gut barrier function in cell and animal models. Research-use-only labels do not make a compound approved; see research use only, explained. For other gut-targeted peptides, see linaclotide and PN-943.

Frequently asked questions about larazotide acetate

Is larazotide a peptide?

Yes. It is a linear chain of eight amino acids, GGVLVQPG, used in trials as the acetate salt.

Is larazotide acetate FDA approved?

No. Its phase 3 celiac trial was terminated in 2022, and the sponsor ended celiac development.

Why was the phase 3 celiac trial stopped?

An interim analysis showed that too many extra patients would be needed to detect a significant effect.

Is larazotide still being studied?

Academic trials at Massachusetts General Hospital tested it in MIS-C and long COVID. The long COVID trial was completed in June 2026.

Is larazotide the same as AT1001?

Yes, AT1001 is one of its code names. The same code appears for migalastat, an unrelated drug, on ClinicalTrials.gov.

What to know now

  • Structure: linear peptide of 8 amino acids (GGVLVQPG); 725.8 g/mol free peptide.
  • Mechanism: tight junction regulator in cell and mouse studies.
  • Evidence: one of three arms met the primary endpoint in a 342-adult celiac trial.
  • Phase 3: stopped in 2022; celiac development discontinued.
  • Safety: adverse events similar to placebo in published abstracts.
  • Status: not FDA-approved; remaining registered work is academic.

What we’re watching

Posted or published results from the completed long COVID trial at Massachusetts General Hospital. Any new sponsor or registered trial. Related guides: PN-943, glepaglutide and linaclotide.

More for gut

All 11 compounds for gut

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 9810532, larazotide; National Center for Biotechnology Information 2026, PubChem compound summary for CID 44146842, larazotide acetate; Gopalakrishnan 2012, Peptides, 35; Leffler 2015, Gastroenterology, 148; Kelly 2013, Alimentary Pharmacology & Therapeutics, 37; Yonker 2025, Science Translational Medicine, 17; 9 Meters Biopharma 2022a; 9 Meters Biopharma 2022b; 9 Meters Biopharma 2018; Massachusetts General Hospital 2023, AT1001 for the treatment of long COVID; Massachusetts General Hospital 2021, AT1001 for the treatment of COVID-19 related MIS-C; 9 Meters Biopharma 2011. All 12 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 9810532, larazotide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/9810532
  2. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 44146842, larazotide acetate. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/44146842
  3. Gopalakrishnan, S., Durai, M., Kitchens, K., et al. (2012). Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides, 35(1), 86-94. https://doi.org/10.1016/j.peptides.2012.02.015
  4. Leffler, D. A., Kelly, C. P., Green, P. H., et al. (2015). Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: A randomized controlled trial. Gastroenterology, 148(7), 1311-1319.e6. https://doi.org/10.1053/j.gastro.2015.02.008
  5. Kelly, C. P., Green, P. H., Murray, J. A., et al. (2013). Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: A randomised placebo-controlled study. Alimentary Pharmacology & Therapeutics, 37(2), 252-262. https://doi.org/10.1111/apt.12147
  6. Yonker, L. M., Kane, A. S., Swank, Z., et al. (2025). Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. Science Translational Medicine, 17(809), eadu4284. https://doi.org/10.1126/scitranslmed.adu4284
  7. 9 Meters Biopharma. (2022a, June 21). 9 Meters Biopharma announces interim analysis of Phase 3 study of larazotide for celiac disease does not support trial continuation [Press release, Form 8-K exhibit 99.1]. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1551986/000155198622000046/ex-991pressreleasedated621.htm
  8. 9 Meters Biopharma. (2022b, August 15). 9 Meters Biopharma provides business update and reports financial results for second quarter 2022 [Press release, Form 8-K exhibit 99.1]. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1551986/000155198622000090/ex-991pressrelease81522.htm
  9. 9 Meters Biopharma, Inc. (2018). Study to evaluate the efficacy and safety of larazotide acetate for the relief of CeD symptoms (ClinicalTrials.gov ID NCT03569007). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03569007
  10. Massachusetts General Hospital. (2023). AT1001 for the treatment of long COVID (ClinicalTrials.gov ID NCT05747534). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05747534
  11. Massachusetts General Hospital. (2021). AT1001 for the treatment of COVID-19 related MIS-C (ClinicalTrials.gov ID NCT05022303). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05022303
  12. 9 Meters Biopharma, Inc. (2011). A double-blind placebo-controlled study to evaluate larazotide acetate for the treatment of celiac disease (ClinicalTrials.gov ID NCT01396213). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01396213